ROYALTY PHARMA PLC
Get an alert when ROYALTY PHARMA PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£460m
USD 618,696,000
-33.4% vs 2024
Net assets
£12bn
USD 16,768,516,000
+8.1% highest in 3 filed years
Employees
—
Average over period
Profit before tax
£1.9bn
USD 2,574,232,000
+790.9% highest in 3 filed years
Net assets
3-year trend · vs Consumer Discretionary median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | — | — | — | — | |
| Operating profit | — | £536,279,450 | £1,893,392,048 | +253.1% | |
| Profit before tax | £1,725,083,612 | £214,747,677 | £1,913,215,905 | +790.9% | |
| Net profit | £1,725,083,612 | £214,747,677 | £1,913,215,905 | +790.9% | |
| Cash | £354,522,482 | £690,468,971 | £459,826,087 | -33.4% | |
| Total assets less current liabilities | £18,714,651,802 | £18,534,393,906 | £20,754,405,797 | +12% | |
| Net assets | £11,856,518,023 | £11,532,202,899 | £12,462,665,180 | +8.1% | |
| Equity | £11,856,518,023 | £11,532,202,899 | £12,462,665,180 | +8.1% | |
| Average employees | — | — | — | — | |
| Wages | — | — | — | — | |
| Directors' remuneration | — | — | — | — |
Figures converted to GBP from USD at 0.743 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Return on capital employed | — | 2.9% | 9.1% | |
| Gearing (liabilities / total assets) | 37.0% | 40.8% | 41.3% | |
| Current ratio | 23.22x | 1.44x | 2.43x | |
| Interest cover | — | 3.20x | 8.28x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- ROYALTY PHARMA PLC 2020-04-22 → present
- ROYALTY PHARMA LTD 2020-02-06 → 2020-04-22
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Consolidated group
- Auditor
- Ernst & Young Chartered Accountants
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on our work, we have not identified any material uncertainties relating to events or conditions that may cast significant doubt on the group and parent company's ability to continue as a going concern for at least twelve months from when the financial statements are authorised for issue.”
Group structure
- ROYALTY PHARMA PLC · parent
- Royalty Pharma Holdings Ltd 74.28%
- RPI US Feeder SPV, LLC
- RPI International Feeder SPV, LLC
- PL RPH Holdings AIV SPV, LLC
- RP MIP Holdings SPV, LLC
- PL RPH Holdings SPV, LLC
- Royalty Pharma Investments 2019 ICAV 74.28%
- Royalty Pharma Development Funding, LLC 74.28%
- Royalty Pharma Finance Corporation 74.28%
- Royalty Pharma Investments 2023 ICAV 74.28%
- RPI 2019 Intermediate Finance Trust 74.28%
- ImmuNext, LLC 74.28%
- Royalty Pharma Manager, LLC 74.29%
- Royalty Pharma Sub-Manager, LLC 74.29%
- Royalty Pharma, LLC 74.29%
- Royalty Pharma Sub-Manager A, LLC 74.29%
- Royalty Pharma Investments ICAV 61.22%
- RPI Acquisitions (Ireland) Limited 61.22%
- Royalty Pharma Investments 2011 ICAV 61.22%
- RPI Finance Trust 61.22%
- Royalty Pharma Collection Trust 63.83%
- RP IP HoldCo (Ireland) Limited 63.83%
Significant events
- “On January 1, 2026, the Company's Board of directors approved a dividend of $0.235 per Class A ordinary share, which was paid on March 10, 2026.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
11 active · 6 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| COMPUTERSHARE COMPANY SECRETARIAL SERVICES LIMITED | Corporate Secretary | 2020-06-05 | — | — |
| BASSLER, Bonnie Lynn | Director | 2020-06-10 | Apr 1962 | American |
| CORIC, Vladimir, Dr | Director | 2025-04-07 | Oct 1970 | American |
| DE SOUZA, Errol | Director | 2020-06-07 | Nov 1953 | American |
| ENGELBERT, Catherine M. | Director | 2020-06-16 | Nov 1964 | American |
| HO, Carole, Dr | Director | 2025-07-17 | Nov 1972 | American |
| HODGSON, David C. | Director | 2022-06-23 | Nov 1956 | American |
| LEGORRETA, Pablo | Director | 2020-02-06 | Oct 1963 | American |
| LOVE, Ted Wendell | Director | 2020-07-31 | Mar 1959 | American |
| NORDEN, Gregory | Director | 2020-06-07 | Oct 1957 | American |
| WEATHERMAN, Elizabeth | Director | 2025-07-17 | Feb 1960 | American |
Show 6 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| VISTRA COSEC LIMITED | Corporate Secretary | 2020-02-06 | 2020-06-05 |
| FERNANDEZ, Henry Alberto | Director | 2020-07-31 | 2025-08-13 |
| FORD, William E. | Director | 2020-06-07 | 2022-06-23 |
| GIULIANI, Mario Germano | Director | 2020-06-07 | 2024-06-06 |
| LLOYD, George Wingate | Director | 2020-04-09 | 2020-06-07 |
| RIGGS, Rory B. | Director | 2020-06-07 | 2024-06-06 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Legorreta Pablo | Individual | Shares 75–100%, Voting 75–100%, Appoints directors | 2020-02-06 | Ceased 2020-06-16 |
Filing timeline
Last 20 of 279 total filings
Material constitutional events — rename, articles re-file, resolution
- 2026-06-18 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-07-25 | AA | accounts | Accounts with accounts type group | |
| 2026-07-24 | SH01 | capital | Capital allotment shares | |
| 2026-07-24 | SH01 | capital | Capital allotment shares | |
| 2026-07-21 | SH03 | capital | Capital return purchase own shares | |
| 2026-07-07 | SH01 | capital | Capital allotment shares | |
| 2026-07-07 | SH01 | capital | Capital allotment shares | |
| 2026-07-07 | SH01 | capital | Capital allotment shares | |
| 2026-07-07 | SH06 | capital | Capital cancellation shares | |
| 2026-07-07 | SH03 | capital | Capital return purchase own shares | |
| 2026-07-02 | SH03 | capital | Capital return purchase own shares | |
| 2026-06-19 | SH01 | capital | Capital allotment shares | |
| 2026-06-19 | SH01 | capital | Capital allotment shares | |
| 2026-06-18 | RESOLUTIONS | resolution | Resolution | |
| 2026-06-18 | SH08 | capital | Capital name of class of shares | |
| 2026-06-17 | SH03 | capital | Capital return purchase own shares | |
| 2026-06-07 | TM01 | officers | Termination director company with name termination date | |
| 2026-06-03 | SH01 | capital | Capital allotment shares | |
| 2026-06-01 | SH03 | capital | Capital return purchase own shares | |
| 2026-06-01 | SH03 | capital | Capital return purchase own shares | |
| 2026-05-28 | SH03 | capital | Capital return purchase own shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 20
- Capital events
- 17
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.